Charles Schwab Investment Management Inc. Increases Stock Position in TransMedics Group, Inc. $TMDX

Key Points

• Charles Schwab Investment Management Inc. increased its stake in TransMedics Group, Inc. by 2.3% to a total of 304,367 shares, valued at approximately $20.5 million.
• Several hedge funds have recently adjusted their positions in TransMedics, with GAMMA Investing LLC boosting its stake by an impressive 551.7% in the first quarter.
• Equities analysts are optimistic about TransMedics, with Canaccord Genuity and Oppenheimer raising their target prices to $142.00 and $150.00 respectively, suggesting strong market confidence in the stock.

Charles Schwab Investment Management Inc. raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 2.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 304,367 shares of the company's stock after buying an additional 6,934 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.90% of TransMedics Group worth $20,478,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. NBC Securities Inc. purchased a new stake in shares of TransMedics Group during the first quarter worth $25,000. Hager Investment Management Services LLC grew its holdings in shares of TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the period. CWM LLC grew its holdings in shares of TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after purchasing an additional 155 shares during the period. GAMMA Investing LLC grew its holdings in shares of TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after purchasing an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. grew its holdings in shares of TransMedics Group by 46.7% in the first quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock valued at $148,000 after purchasing an additional 700 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Up 1.9%

NASDAQ:TMDX traded up $2.20 during mid-day trading on Wednesday, hitting $117.38. The stock had a trading volume of 668,926 shares, compared to its average volume of 1,240,400. The stock has a 50-day simple moving average of $120.56 and a two-hundred day simple moving average of $102.19. The company has a market capitalization of $4.00 billion, a PE ratio of 60.82 and a beta of 2.09. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $176.32. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same quarter last year, the company earned $0.35 earnings per share. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on TMDX. Morgan Stanley increased their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus price target of $123.00.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.